Kulikov A.Y. 21802

A pharmacoeconomic analysis of dual antiplatelet therapy with acetylsalicylic acid and ticagrelor in patients with acute coronary syndrome undergoing percutaneous coronary intervention

Introduction. On average, about 520,000 cases of acute coronary syndrome (ACS) are registered annually in Russia, and 41,136 patients in 2013 underwent percutaneous coronary intervention (PCI). Every year Russia loses from 100,000 to 120,000 years of life of the working-age population, predominantly male, which leads to a significant loss of the working-age population of the country and presents a significant threat to social and economic welfare of society [8]. The use of more effective antiplatelet therapy in ACS patients can improve outcomes, thus contributing to the reduction in cardiovascular mortality and improving long-term prognosis.
Objectives. The aim of this study was to perform a comparative pharmacoeconomic analysis of ticagrelor + ASA and clopidogrel + ASA therapy in patients with ACS undergoing PCI in the context of the Russian health system.
Results. Analysis of effectiveness revealed that effectiveness of ticagrelor + ASA treatment regimen was higher. Cost-effectiveness analysis showed that ticagrelor + ASA was a dominant therapy considering average prices in Russia by the results of tenders, as well as ticagrelor price planned for registration in the Essential Medicines List and prices for clopidogrel registered in the Essential Medicines List. According to the results of budget impact analysis, the use of ticagrelor + ASA regimen leads to money saving considering average prices in the Russian Federation by the results of tenders, as well as ticagrelor price planned for registration in the Essential Medicines List and price of Clopidogrel registered in the Essential Medicines List.
Conclusion. Therapy of acute coronary syndrome patients managed with PCI with combination of ticagrelor and ASA is economically preferable in comparison with therapy with combination of clopidogrel and ASA
Скорее всего ваш браузер не поддерживает PDF и Adobe Reader, нажмите здесь, чтобы просмотреть PDF

Comments0